GSK Gets New Start For Breo With FDA Approval In Asthma

FDA approved Breo Ellipta as a once-daily treatment for asthma, a new indication for a drug that has been on the market since October 2013 for COPD.

GlaxoSmithKline PLC will have a new opportunity to jumpstart sales of Breo Ellipta (fluticasone furoate/vilanterol) after FDA approved the drug as a once-daily treatment for asthma for patients 18 and older April 30.

The fixed-dose combination of the inhaled corticosteroid fluticasone and the long-acting beta2-agonist (LABA) vilanterol administered via the Ellipta dry powder inhaler has been on the market since October 2013 for the treatment of chronic obstructive

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approvals

More from Product Reviews